Sai‐Hong Ignatius Ou
YOU?
Author Swipe
View article: The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial Open
Purpose: PI3K/mTOR pathway activation drives oncogenesis and progression of many cancers. RMC-5552 is a bi-steric, mTOR complex 1 (mTORC1)-selective inhibitor that potently inhibits phosphorylation of key mTORC1 substrates eukaryotic initi…
View article: A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025
A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 Open
Splice site mutations around or within exon 14 of MET (METex14+) are rare, but are one of the common actionable driver mutations in elderly patients with non-small cell lung cancer (NSCLC). Globally, only two MET tyrosine kinase inhibitors…
View article: Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib Open
This is the first patient case report with >24 months on-going follow-up demonstrating that gilteritinib could be repurposed as a potent and tolerable ALK inhibitor based on previously reported pre-clinical activity and with potential CNS …
View article: Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study Open
The safety profile was consistent with previous reports of amivantamab in EGFR-mutant NSCLC. Amivantamab demonstrated clinically meaningful and durable antitumor activity in participants with METex14 advanced NSCLC, including those who pro…
View article: LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154) Open
The current standard of care for unresectable stage III non-small cell lung cancer (NSCLC) involves a concurrent platinum-based doublet chemotherapy and chest radiotherapy, followed by consolidative therapy with durvalumab, an anti-program…
View article: Multiomic Characterization of <i>RCC1</i> and <i>RCC2</i> Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes
Multiomic Characterization of <i>RCC1</i> and <i>RCC2</i> Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes Open
PURPOSE Regulator of chromosome condensation 1 ( RCC1 ) and RCC2 have been shown to play important roles in the regulation of cell cycle, DNA damage response, and nucleocytoplasmic transport. MATERIALS AND METHODS DNA (592-gene or whole ex…
View article: Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive Cancer
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive Cancer Open
Zenocutuzumab showed efficacy in patients with advanced NRG1 fusion-positive cancer, notably NSCLC and pancreatic cancer, with mainly low-grade adverse events. (Funded by Merus; eNRGy ClinicalTrials.gov number, NCT02912949.).
View article: Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC
Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC Open
A substantial proportion of BRAF+ NSCLC patients exhibited a TMB ≥ 10, among all three classes of BRAF mutation classification, including BRAF V600E+ NSCLC. Class III mutations appeared to have the highest median TMB, followed by class II,…
View article: Tumor Mutation Burden Survey of AACR GENIE Database Revealed NTRK (<scp><i>NTRK</i></scp>+) and RET (<scp><i>RET</i></scp>+) Fusions Positive Colorectal Carcinoma (CRC) as Distinct Subsets
Tumor Mutation Burden Survey of AACR GENIE Database Revealed NTRK (<span><i>NTRK</i></span>+) and RET (<span><i>RET</i></span>+) Fusions Positive Colorectal Carcinoma (CRC) as Distinct Subsets Open
Background Receptor tyrosine kinase (RTK) inhibitors have been approved for the treatment of NTRK fusion ( NTRK +) and RET fusion ( RET +) positive solid tumors in a tumor‐agnostic manner. However, the objective response rate was the lowes…
View article: Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report
Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report Open
gov NCT01970865.
View article: Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis Carcinoma
Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis Carcinoma Open
PURPOSE Nuclear protein in testis carcinoma (NC) is an underdiagnosed and aggressive squamous/poorly differentiated cancer characterized by rearrangement of the gene NUTM1 on chromosome 15q14. Co-occurring alternations have not been fully …
View article: Supplemental Figure 4 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplemental Figure 4 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients Open
Supplemental Figure 4: Radiographic response of patients that cleared their plasma (teal) at cycle 4 versus that did not (red).
View article: Supplemental Figure 3 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplemental Figure 3 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients Open
Supplemental Figure 3: Baseline AF% of patients with complete clearance and patients with incomplete clearance at C2.
View article: Supplementary Data 1 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplementary Data 1 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients Open
Demographics and Baseline Characteristics
View article: Supplemental Figure 3 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplemental Figure 3 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients Open
Supplemental Figure 3: Baseline AF% of patients with complete clearance and patients with incomplete clearance at C2.
View article: Data from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Data from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients Open
Purpose: Non-invasive monitoring of circulating tumor DNA (ctDNA) has the potential to be a readily available measure for early prediction of clinical response. Here we report on early ctDNA changes of KRAS G12C in a Phase 2 trial of adagr…
View article: Supplemental Figure 1 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplemental Figure 1 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients Open
Supplemental Figure 1: Quantitative concordance between NGS and ddPCR KRASG12C results. ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction.
View article: Supplementary Data 1 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplementary Data 1 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients Open
Demographics and Baseline Characteristics
View article: Supplemental Figure 2 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplemental Figure 2 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients Open
Supplemental Figure 2: Baseline AF% vs sum of diameter (SOD) at baseline.
View article: Supplemental Figure 1 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplemental Figure 1 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients Open
Supplemental Figure 1: Quantitative concordance between NGS and ddPCR KRASG12C results. ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction.
View article: Supplemental Figure 2 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplemental Figure 2 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients Open
Supplemental Figure 2: Baseline AF% vs sum of diameter (SOD) at baseline.
View article: Supplemental Figure 4 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplemental Figure 4 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients Open
Supplemental Figure 4: Radiographic response of patients that cleared their plasma (teal) at cycle 4 versus that did not (red).
View article: Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey. Open
The year 2024 is the 20th anniversary of the discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Since then, tremendous advances have been made in the treatment of NSCLC based on…